WO2008027338A3 - Antagonistic human light-specific human monoclonal antibodies - Google Patents

Antagonistic human light-specific human monoclonal antibodies Download PDF

Info

Publication number
WO2008027338A3
WO2008027338A3 PCT/US2007/018832 US2007018832W WO2008027338A3 WO 2008027338 A3 WO2008027338 A3 WO 2008027338A3 US 2007018832 W US2007018832 W US 2007018832W WO 2008027338 A3 WO2008027338 A3 WO 2008027338A3
Authority
WO
WIPO (PCT)
Prior art keywords
hlight
antibodies
fully human
polypeptide
immunospecifically bind
Prior art date
Application number
PCT/US2007/018832
Other languages
French (fr)
Other versions
WO2008027338A2 (en
Inventor
Steven W Granger
Shinichiro Kato
Carl F Ware
Original Assignee
Kirin Pharma Kk
Jolla Inst Allergy Immunolog
Steven W Granger
Shinichiro Kato
Carl F Ware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39126775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008027338(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2661782A priority Critical patent/CA2661782C/en
Priority to BRPI0716088A priority patent/BRPI0716088B8/en
Priority to KR1020097006317A priority patent/KR101314362B1/en
Priority to US12/439,518 priority patent/US8058402B2/en
Priority to EP07837385A priority patent/EP2064243A2/en
Priority to CN200780040270.3A priority patent/CN101663321B/en
Priority to KR1020137011247A priority patent/KR101374983B1/en
Priority to NZ575163A priority patent/NZ575163A/en
Priority to AU2007290570A priority patent/AU2007290570C1/en
Application filed by Kirin Pharma Kk, Jolla Inst Allergy Immunolog, Steven W Granger, Shinichiro Kato, Carl F Ware filed Critical Kirin Pharma Kk
Priority to JP2009526670A priority patent/JP5209625B2/en
Priority to EA200970234A priority patent/EA021255B1/en
Priority to MX2009002151A priority patent/MX2009002151A/en
Publication of WO2008027338A2 publication Critical patent/WO2008027338A2/en
Publication of WO2008027338A3 publication Critical patent/WO2008027338A3/en
Priority to TN2009000051A priority patent/TN2009000051A1/en
Priority to IL197158A priority patent/IL197158A/en
Priority to MA31722A priority patent/MA31347B1/en
Priority to NO20091235A priority patent/NO20091235L/en
Priority to US13/240,356 priority patent/US8461307B2/en
Priority to IL216381A priority patent/IL216381A0/en
Priority to US13/889,608 priority patent/US8974787B2/en
Priority to US14/611,965 priority patent/US9771419B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Provided herein are antibodies, such as fully human antibodies, that immunospecifically bind to an hLIGHT polypeptide. Also provided are isolated nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Further provided are vectors and host cells comprising nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided are methods of making antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided herein is a method of treating a hLIGHT- mediated disease in a subject comprising administering to the subject an antibody, such as a fully human antibody, that immunospecifically binds to a hLIGHT polypeptide. In preferred embodiments, that anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT- mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
PCT/US2007/018832 2006-08-28 2007-08-24 Antagonistic human light-specific human monoclonal antibodies WO2008027338A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
BRPI0716088A BRPI0716088B8 (en) 2006-08-28 2007-08-24 isolated antibody, composition, isolated nucleic acid molecule, vector, method for producing an antibody, hybridoma, and kit
EA200970234A EA021255B1 (en) 2006-08-28 2007-08-24 Antagonistic human light-specific human monoclonal antibodies
JP2009526670A JP5209625B2 (en) 2006-08-28 2007-08-24 Antagonist human LIGHT specific human monoclonal antibody
US12/439,518 US8058402B2 (en) 2006-08-28 2007-08-24 Antagonistic human LIGHT-specific human monoclonal antibodies
EP07837385A EP2064243A2 (en) 2006-08-28 2007-08-24 Antagonistic human light-specific human monoclonal antibodies
CN200780040270.3A CN101663321B (en) 2006-08-28 2007-08-24 Antagonistic human light-specific human monoclonal antibodies
KR1020137011247A KR101374983B1 (en) 2006-08-28 2007-08-24 Pharmaceutical composition comprising antagonistic human light-specific human monoclonal antibodies
NZ575163A NZ575163A (en) 2006-08-28 2007-08-24 Antagonistic human light-specific human monoclonal antibodies
AU2007290570A AU2007290570C1 (en) 2006-08-28 2007-08-24 Antagonistic human LIGHT-specific human monoclonal antibodies
MX2009002151A MX2009002151A (en) 2006-08-28 2007-08-24 Antagonistic human light-specific human monoclonal antibodies.
KR1020097006317A KR101314362B1 (en) 2006-08-28 2007-08-24 Antagonistic human light-specific human monoclonal antibodies
CA2661782A CA2661782C (en) 2006-08-28 2007-08-24 Antagonistic human light-specific human monoclonal antibodies
TN2009000051A TN2009000051A1 (en) 2006-08-28 2009-02-17 Antagonistic human light-specific human monoclonal antibodies
IL197158A IL197158A (en) 2006-08-28 2009-02-19 Isolated antibody that immuno-specifically binds to a human light, a composition comprising same and use thereof for preparation of a medicament
MA31722A MA31347B1 (en) 2006-08-28 2009-03-18 Human monoclonal antibodies.
NO20091235A NO20091235L (en) 2006-08-28 2009-03-24 Antagonistic human light-specific monoclonal antibodies
US13/240,356 US8461307B2 (en) 2006-08-28 2011-09-22 Antagonistic human LIGHT-specific human monoclonal antibodies
IL216381A IL216381A0 (en) 2006-08-28 2011-11-15 Antagonistic human light-specific human monoclonal antibodies
US13/889,608 US8974787B2 (en) 2006-08-28 2013-05-08 Antagonistic human light-specific human monoclonal antibodies
US14/611,965 US9771419B2 (en) 2006-08-28 2015-02-02 Antagonistic human light-specific human monoclonal antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84077406P 2006-08-28 2006-08-28
US60/840,774 2006-08-28
US89787507P 2007-01-25 2007-01-25
US60/897,875 2007-01-25

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/439,518 A-371-Of-International US8058402B2 (en) 2006-08-28 2007-08-24 Antagonistic human LIGHT-specific human monoclonal antibodies
US13/240,356 Continuation US8461307B2 (en) 2006-08-28 2011-09-22 Antagonistic human LIGHT-specific human monoclonal antibodies
US13/240,356 Continuation-In-Part US8461307B2 (en) 2006-08-28 2011-09-22 Antagonistic human LIGHT-specific human monoclonal antibodies

Publications (2)

Publication Number Publication Date
WO2008027338A2 WO2008027338A2 (en) 2008-03-06
WO2008027338A3 true WO2008027338A3 (en) 2008-07-24

Family

ID=39126775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018832 WO2008027338A2 (en) 2006-08-28 2007-08-24 Antagonistic human light-specific human monoclonal antibodies

Country Status (30)

Country Link
US (4) US8058402B2 (en)
EP (3) EP2484696B1 (en)
JP (2) JP5209625B2 (en)
KR (2) KR101314362B1 (en)
AU (1) AU2007290570C1 (en)
BR (1) BRPI0716088B8 (en)
CA (1) CA2661782C (en)
CO (1) CO6170363A2 (en)
CR (1) CR10652A (en)
CY (1) CY1114719T1 (en)
DK (2) DK2484696T3 (en)
EA (1) EA021255B1 (en)
ES (2) ES2643687T3 (en)
GT (1) GT200900043A (en)
HK (1) HK1153209A1 (en)
HR (1) HRP20131215T1 (en)
IL (2) IL197158A (en)
MA (1) MA31347B1 (en)
MX (1) MX2009002151A (en)
MY (1) MY162024A (en)
NI (1) NI200900027A (en)
NO (1) NO20091235L (en)
NZ (2) NZ575163A (en)
PL (1) PL2292663T3 (en)
PT (1) PT2292663E (en)
RS (1) RS53120B (en)
SG (1) SG170032A1 (en)
TN (1) TN2009000051A1 (en)
TW (2) TWI405771B (en)
WO (1) WO2008027338A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05002514A (en) * 2002-09-06 2005-05-27 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody.
EA021255B1 (en) * 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Antagonistic human light-specific human monoclonal antibodies
WO2009039310A2 (en) * 2007-09-18 2009-03-26 La Jolla Institute For Allergy And Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
US9700606B2 (en) * 2008-07-08 2017-07-11 La Jolla Institute For Allergy And Immunology HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of use
MX338825B (en) 2008-10-02 2016-05-03 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins.
AU2010228990A1 (en) * 2009-03-24 2011-10-27 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against LIGHT and uses thereof
CA2854809A1 (en) 2011-11-15 2013-05-23 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders
ES2702246T3 (en) * 2012-03-26 2019-02-28 Sanofi Sa Stable IgG4 binding agent formulations
US20130315913A1 (en) 2012-03-26 2013-11-28 Sanofi Anti-light antibody therapy for inflammatory bowel disease
EP3431104A1 (en) 2012-03-26 2019-01-23 Sanofi Stable igg4 binding agent formulations
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
JP6153019B2 (en) 2013-01-31 2017-06-28 国立大学法人 東京大学 Compound having lysophosphatidylserine receptor function modulating activity
US10259880B2 (en) 2014-01-14 2019-04-16 Kymab Limited Anti-LIGHT antibodies
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI555513B (en) * 2014-05-27 2016-11-01 奇美醫療財團法人奇美醫院 Monitoring device and monitoring method of stenosis
JP6369721B2 (en) 2014-07-04 2018-08-08 国立大学法人 東京大学 Lysophosphatidylserine derivative
MA41414A (en) * 2015-01-28 2017-12-05 Centre Nat Rech Scient ICOS AGONIST BINDING PROTEINS
WO2017035010A1 (en) * 2015-08-21 2017-03-02 The Children's Hospital Of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
KR102616436B1 (en) 2016-12-14 2023-12-27 비오라 쎄라퓨틱스, 인크. Treatment of gastrointestinal diseases with TNF inhibitors
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
KR20210095165A (en) 2018-11-19 2021-07-30 프로제너티, 인크. Methods and devices for treating diseases with biopharmaceuticals
TW202124425A (en) 2019-09-13 2021-07-01 日商協和麒麟股份有限公司 Dcr3 variant
CA3162181A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology Antibodies directed to tie-2 and methods of use
CN115666704A (en) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 Ingestible device for delivery of therapeutic agents to the gastrointestinal tract
CN115768791B (en) * 2020-04-01 2024-05-24 阿瓦洛治疗公司 Methods and treatments involving excess free LIGHT
WO2023133389A2 (en) * 2022-01-05 2023-07-13 Avalo Therapeutics, Inc. Methods of treating asthma with anti-light antibodies
WO2024067344A1 (en) * 2022-09-27 2024-04-04 舒泰神（北京）生物制药股份有限公司 Antibody for specifically recognizing light and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089575A2 (en) * 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5

Family Cites Families (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627366A (en) 1899-06-20 John treleaven
US452281A (en) 1891-05-12 Railway signaling device
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ATE37983T1 (en) 1982-04-22 1988-11-15 Ici Plc DELAYED RELEASE AGENT.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
JP2532858B2 (en) 1985-04-01 1996-09-11 セルテツク リミテツド Transformed myeloma cell line
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE68921982D1 (en) 1988-06-14 1995-05-04 Cetus Oncology Corp COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE151110T1 (en) 1988-09-02 1997-04-15 Protein Eng Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING SITES
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
KR900005995A (en) 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (en) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Chimeric antibodies having receptor binding ligands instead of constant regions
IT1246382B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH07500961A (en) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット Targeting viruses and cells for selective internalization by cells
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
ATE218889T1 (en) 1990-11-09 2002-06-15 Stephen D Gillies CYTOKINE IMMUNOCONJUGATES
JP3242916B2 (en) 1990-12-14 2001-12-25 セル ジェネシス，インコーポレイティド Chimeric chains for receptor-related signal transduction systems
JP3672306B2 (en) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート Heterodimeric receptor library using phagemids
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
AU668870B2 (en) 1991-05-14 1996-05-23 Targetech, Inc Targeted delivery of genes encoding immunogenic proteins
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE275198T1 (en) 1991-12-02 2004-09-15 Medical Res Council PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES.
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0656946T4 (en) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobulins without light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP3789930B2 (en) 1992-10-09 2006-06-28 アドバンスド ティシュー サイエンシズ，インコーポレーテッド Liver spare cells
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
WO1995002420A2 (en) 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Prodrugs of protein tyrosine kinase inhibitors
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
US5925376C1 (en) 1994-01-10 2001-03-20 Madalene C Y Heng Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
US5618709A (en) 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
WO1995020401A1 (en) 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CN1117155C (en) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 Novel compounds
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5911995A (en) 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
DK0805628T3 (en) 1995-01-17 2003-07-14 Brigham & Womens Hospital Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5998596A (en) 1995-04-04 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of protein kinase activity by aptameric action of oligonucleotides
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0841068B1 (en) 1995-06-01 2006-07-12 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6127366A (en) 1995-11-22 2000-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE69620445T2 (en) 1995-12-08 2002-12-12 Janssen Pharmaceutica Nv (IMIDAZOL-5-YL) METHYL-2-CHINOLINO DERIVATIVES AS A FARNESYL PROTEIN TRANSFERASE INHIBITOR
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5958769A (en) 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
US6090948A (en) 1996-01-30 2000-07-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997027852A1 (en) 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
US6479254B2 (en) 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19617461A1 (en) 1996-05-02 1997-11-06 Bayer Ag Acylmercapto triazolyl derivatives
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5648239A (en) 1996-06-21 1997-07-15 Incyte Pharmaceuticals, Inc. Human camp-dependent protein kinase inhibitor homolog
BR9709974A (en) 1996-06-27 1999-08-10 Pfizer 2- (2-Oxo-Ethidylene) -imidazolidin-4-one derivatives and their use as farnesyl protein transferase inhibitors
ATE275630T1 (en) 1996-07-19 2004-09-15 Takeda Chemical Industries Ltd FAS LIGAND-LIKE PROTEIN, ITS PRODUCTION AND USE
CA2263425C (en) 1996-08-12 2008-09-30 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical agent containing rho kinase inhibitor
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US6040305A (en) 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5945429A (en) 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6093737A (en) 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
AU5772698A (en) 1997-01-29 1998-08-18 Zeneca Limited Inhibitors of farnesyl protein transferase
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
CZ294425B6 (en) 1997-04-14 2005-01-12 Micromet Ag Process for preparing anti-human antigen receptor, anti-human antigen receptor per se, VH and VL chain, kit for the selection of anti-human antigen receptors and pharmaceutical composition containing such a receptor
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6051582A (en) 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
UA61970C2 (en) 1997-08-15 2003-12-15 Combined use of tyrosine kinase inhibitor and a chemical castration agent for treating prostate cancer
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6103723A (en) 1997-10-17 2000-08-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE205195T1 (en) 1997-10-22 2001-09-15 Astrazeneca Ab IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
US6410539B1 (en) 1997-10-22 2002-06-25 Astrazenca Uk Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
SE512663C2 (en) 1997-10-23 2000-04-17 Biogram Ab Active substance encapsulation process in a biodegradable polymer
DE69839179T2 (en) 1997-10-28 2009-02-19 Bando Chemical Industries, Ltd., Kobe DERMATOLOGICAL PLASTER AND METHOD FOR PRODUCING ITS BASE LAYER
EP1042343B1 (en) 1997-11-03 2008-01-23 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
US6124465A (en) 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
CA2310629A1 (en) 1997-11-28 1999-06-10 Tae Hwan Kwak Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
US6054466A (en) 1997-12-04 2000-04-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6335156B1 (en) 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle
ES2185307T3 (en) 1998-02-02 2003-04-16 Lg Chemical Ltd FARNESIL TRANSFERASA INHIBITORS THAT HAVE A PIPERIDINIC STRUCTURE AND PROCEDURE FOR THEIR PREPARATION.
AU2972199A (en) 1998-02-20 1999-09-06 Reinhard Ebner Apoptosis inducing molecule ii and methods of use
JP2002513031A (en) 1998-04-27 2002-05-08 ワーナー−ランバート・カンパニー Glycinamide derivatives with functionalized alkyl and alkenyl side chains as farnesyltransferase inhibitors
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
HU229358B1 (en) 1998-07-06 2013-11-28 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6362188B1 (en) 1998-12-18 2002-03-26 Schering Corporation Farnesyl protein transferase inhibitors
FR2787327B1 (en) 1998-12-21 2003-01-17 Aventis Pharma Sa COMPOSITIONS CONTAINING FARNESYL TRANSFERASE INHIBITORS
US6432959B1 (en) 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
JP4876239B2 (en) 1999-01-11 2012-02-15 プリンストン ユニバーシティー High affinity inhibitors for target confirmation and use thereof
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6143766A (en) 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
CA2374273A1 (en) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Liver function controlling agents
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6458935B1 (en) 1999-06-23 2002-10-01 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
ATE440111T1 (en) 1999-11-29 2009-09-15 Bac Ip B V IMMOBILIZED ANTIGEN BINDING MOLECULES FROM A DOMAIN
US6403581B1 (en) 2000-01-19 2002-06-11 American Cyanamid Company Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2001079496A2 (en) 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
EP1317284A2 (en) 2000-09-08 2003-06-11 Micromet AG Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
ES2405944T3 (en) * 2000-11-30 2013-06-04 Medarex, Inc. Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas
CA2439193A1 (en) 2001-02-23 2002-08-29 Hideki Matsui Casoase 3 inhibitors
US7476536B2 (en) 2001-05-11 2009-01-13 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody a light chain gene
US20040176320A1 (en) 2001-06-29 2004-09-09 Jari Natunen Use of at least one glycoinhibitor substance
US20040038349A1 (en) 2001-07-27 2004-02-26 Hilbert David M. Heteromultimeric TNF ligand family members
AR035119A1 (en) 2001-08-16 2004-04-14 Lilly Co Eli ANTI-HTNFSF13B HUMAN ANTI-BODIES
EP1336619A3 (en) 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
AU2003224952A1 (en) 2002-04-15 2003-11-03 Thomas F. C. Allnutt Incorporation of anaerobic bacteria in feed formulation
EP1660534A2 (en) 2003-08-22 2006-05-31 MedImmune, Inc. Humanization of antibodies
WO2006063067A2 (en) 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
EA021255B1 (en) * 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Antagonistic human light-specific human monoclonal antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089575A2 (en) * 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAMADA KOJI ET AL: "Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 3, March 2000 (2000-03-01), pages 283 - 289, XP002246831, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
EA200970234A1 (en) 2010-02-26
US20130230536A1 (en) 2013-09-05
EP2292663A3 (en) 2011-11-23
TN2009000051A1 (en) 2010-08-19
MA31347B1 (en) 2010-05-03
US20100021466A1 (en) 2010-01-28
NZ575163A (en) 2011-12-22
US8974787B2 (en) 2015-03-10
EA021255B1 (en) 2015-05-29
BRPI0716088A8 (en) 2020-03-31
DK2292663T3 (en) 2013-11-04
CA2661782C (en) 2019-04-16
IL197158A (en) 2014-09-30
IL197158A0 (en) 2011-08-01
TW200825104A (en) 2008-06-16
PT2292663E (en) 2013-11-04
KR20090057285A (en) 2009-06-04
EP2292663A2 (en) 2011-03-09
US9771419B2 (en) 2017-09-26
CR10652A (en) 2009-05-13
KR20130064814A (en) 2013-06-18
HK1153209A1 (en) 2012-03-23
US8461307B2 (en) 2013-06-11
NI200900027A (en) 2011-10-25
KR101374983B1 (en) 2014-03-17
WO2008027338A2 (en) 2008-03-06
PL2292663T3 (en) 2014-03-31
JP5209625B2 (en) 2013-06-12
JP5751680B2 (en) 2015-07-22
GT200900043A (en) 2010-04-29
CY1114719T1 (en) 2016-10-05
HRP20131215T1 (en) 2014-01-31
ES2439994T3 (en) 2014-01-27
NZ596091A (en) 2012-07-27
MY162024A (en) 2017-05-31
CA2661782A1 (en) 2008-03-06
AU2007290570A2 (en) 2010-09-09
AU2007290570B2 (en) 2013-01-10
US8058402B2 (en) 2011-11-15
AU2007290570A1 (en) 2008-03-06
EP2064243A2 (en) 2009-06-03
TWI405771B (en) 2013-08-21
NO20091235L (en) 2009-04-29
JP2010502183A (en) 2010-01-28
US20150337046A1 (en) 2015-11-26
US20120076798A1 (en) 2012-03-29
CO6170363A2 (en) 2010-06-18
AU2007290570C1 (en) 2013-08-15
IL216381A0 (en) 2011-12-29
TW201343676A (en) 2013-11-01
RS53120B (en) 2014-06-30
KR101314362B1 (en) 2013-10-10
EP2484696A1 (en) 2012-08-08
ES2643687T3 (en) 2017-11-23
SG170032A1 (en) 2011-04-29
BRPI0716088A2 (en) 2013-10-01
MX2009002151A (en) 2009-07-03
EP2484696B1 (en) 2017-08-16
BRPI0716088B1 (en) 2020-12-08
JP2013153749A (en) 2013-08-15
BRPI0716088B8 (en) 2021-05-25
DK2484696T3 (en) 2017-10-02
EP2292663B1 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
WO2008027338A3 (en) Antagonistic human light-specific human monoclonal antibodies
NO20210499A1 (en) Humanized, glycoma-engineered Type II anti-CD20 antibody and its use, as well as host cell and pharmaceutical composition
SG178567A1 (en) Affinity-matured humanized anti cea monoclonal antibodies
WO2008017963A3 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
TW200720439A (en) Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
WO2006082515A3 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
PH12012502376A1 (en) Modified antigen binding molecules with altered cell signaling activity
WO2009155724A3 (en) Stable and soluble antibodies inhibiting vegf
MX2009009379A (en) Methods and compositions for treating tumor diseases.
WO2007092640A3 (en) Antibodies that bind par-2
WO2005058815A3 (en) Ip-10 antibodies and their uses
MX2009013824A (en) Antigen binding proteins that bind par-2.
WO2005016236A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2008124170A3 (en) SELECTION OF HUMAN TNFα SPECIFIC ANTIBODIES
ECSP099192A (en) SPECIFIC HUMAN MONOCLONAL ANTIBODIES FOR HUMAN LIGHT ANTAGONISTS
WO2004016753A3 (en) Antibodies that immunospecifically bind to trail receptors
DOP2009000052A (en) SPECIFIC HUMAN MONOCLONAL ANTIBODIES FOR HUMAN LIGHT ANTAGONISTS
NZ702127A (en) Methods and compositions for diagnosis and treatment of cancer
BRPI0716611A2 (en) chimeric monoclonal antibody, isolated nucleic acid, isolated cell, pharmaceutical composition, and method for treating a disease or disorder

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780040270.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837385

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 197158

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007290570

Country of ref document: AU

Ref document number: 2661782

Country of ref document: CA

Ref document number: 12009500369

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 575163

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/002151

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 0900871

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2009526670

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2009-010652

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 12439518

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 09027214

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: DZP2009000161

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007837385

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1728/CHENP/2009

Country of ref document: IN

Ref document number: 200970234

Country of ref document: EA

Ref document number: 1020097006317

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: A200902921

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 1020137011247

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0716088

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090227